Despite the growing number of studies that demonstrate the importance of empowering parents with knowledge and skills to act as intervention agents for their children with autism spectrum disorder (ASD), there are limited examples of parent-mediated interventions that focus on problem behaviors. Additionally, access to ASD-trained clinicians and research supported delivery options for families in rural areas is severely limited. COMPASS for Hope (C-HOPE) is an 8-week parent intervention program that was developed with the option of telehealth or face-to-face delivery. Parents who received C-HOPE intervention reported a reduction in parenting stress and an increase in competence. Parents also reported significant reductions in child behavior problems, both when compared to pre-intervention levels and to a waitlist control condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10803-017-3333-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rehabilitation Transition Program to Improve Community Participation Among Stroke Survivors: A Randomized Clinical Trial.
JAMA Netw Open
October 2024
Program in Occupational Therapy, Washington University in St Louis School of Medicine, St Louis, Missouri.
Article Synopsis
- Stroke survivors transitioning home need support to overcome new environmental challenges post-rehabilitation.
- The study evaluated the effectiveness of a new rehabilitation program, COMPASS, to enhance daily living and community participation for stroke patients compared to a control group.
- Results indicated no significant differences in community participation improvement between the COMPASS and control groups after 12 months, suggesting similar outcomes for both interventions.
Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
Wellcome Open Res
July 2024
Neuropsychiatry Research and Education Group, King's College London, London, England, UK.
Article Synopsis
- Functional neurological disorder (FND) causes symptoms like paralysis and seizures and can be very serious, leading to high healthcare costs.
- Researchers plan to study the effects of psilocybin (a psychedelic) on people with FND to understand how it might help their condition.
- The study will look at brain activity and other factors related to FND both before and after people take psilocybin, tracking their experiences for three months.
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
Eur Addict Res
October 2024
Division of Brain Sciences, Centre for Psychiatry, Imperial College London, Commonwealth Building, Hammersmith Campus, London, UK.
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid diethylamide [LSD], dimethyltryptamine [DMT], mescaline) and atypical (ketamine, ibogaine, 5-MeO-DMT, 3,4-methylenedioxymethamphetamine) psychedelics for the treatment of addiction.
View Article and Find Full Text PDFHope and relationship dynamics among couples faced with their child's cancer: A dyadic phenomenological interpretative analysis.
Eur J Oncol Nurs
October 2024
Univ. Lille, CNRS, UMR 9193, SCALab - Sciences Cognitives et Sciences Affectives, F-59000, Lille, France. Electronic address:
Purpose: The onset of paediatric cancer leads to changes in the functioning of the parental couple. The interactions and interdependence between partners affect their individual and dyadic adjustments. Hope can enable parents to cope with difficulties and alleviate their distress.
View Article and Find Full Text PDFA Phase 1 single ascending dose study of pure oral harmine in healthy volunteers.
J Psychopharmacol
October 2024
Department of Medicine, Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Article Synopsis
- Harmine, a key ingredient in the hallucinogenic drink Ayahuasca, raises questions about its psychoactive effects, maximum tolerated dose (MTD), and safety in humans when administered in pharmaceutical-grade form.
- A Phase 1 trial with 25 healthy adults tested varying doses of harmine hydrochloride (100-500 mg) to assess safety and potential psychoactivity, identifying the MTD as between 100 and 200 mg while noting mild to moderate gastrointestinal and neurological side effects.
- Results indicate that doses below 2.7 mg/kg of harmine HCl are generally safe with few adverse effects, while higher doses lead to more severe reactions and limited psychoactivity, marking this
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!